Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 Aug 2010

Marmé F, Werft W, Benner A, Burwinkel B, Sinn P, Sohn C, Lichter P, Hahn M, Schneeweiss A

Abstract excerpt

BACKGROUND: A single-nucleotide polymorphism (SNP) in the FGFR4 gene is associated with poor prognosis in solid tumors. A recent study presented the first evidence that FGFR4 Arg388 could predict resistance to adjuvant chemotherapy in breast cancer. The present study evaluates the potential of th...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Arginine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Chemotherapy, Adjuvant

Share to DNA Primers

Share to Immunohistochemistry

Share to Receptor, Fibroblast Growth Factor, Type 4

Share to Remission Induction

Source

Identifiers

PMID: 20147743
DOI: 10.1093/annonc/mdq017

Genes

FGFR4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20147743-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer.PMID 20147743Read ↗

FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.Semantic proximity Read ↗

Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patientsSemantic proximity Read ↗

Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer.Semantic proximity Read ↗

CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer.Semantic proximity Read ↗

Exploratory analysis of candidate germline gene polymorphisms in breast cancer patients treated with neoadjuvant anthracycline-containing chemotherapy and associations with febrile neutropenia.Semantic proximity Read ↗

Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell Carcinoma Patients With Lymph Node Involvement.Semantic proximity Read ↗

FGFR4 profile as a prognostic marker in squamous cell carcinoma of the mouth and oropharynx.Semantic proximity Read ↗

Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor.Semantic proximity Read ↗

FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer.Semantic proximity Read ↗

Identification of SNPs associated with response of breast cancer patients to neoadjuvant chemotherapy in the EORTC-10994 randomized phase III trial.Semantic proximity Read ↗

Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study.Semantic proximity Read ↗

Functional FGFR4 Gly388Arg polymorphism contributes to cancer susceptibility: Evidence from meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.